This Phase 1 study will explore the safety, tolerability, and pharmacokinetics of single
doses ranging from 300 to 600 mg and multiple daily doses ranging from 225 mg to 300 mg BID
dexpramipexole in healthy volunteers.
Drug: Dexpramipexole Placebo
We will connect you to the doctor responsible for this trial and help you get more information.
Locations near you
Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Full eligibility criteria for NCT01449578
Ages eligible for Study
18 Years to 55 Years
Genders eligible for Study
Accepts Healthy Volunteers
Must give written informed consent.
Adult males/females aged 18 to 55 years inclusive and between 19 and 30 kg/m2 body mass index (BMI), inclusive at screening.
Subjects who are healthy as determined by prestudy medical history, physical examination and 12-lead ECG.
Subjects of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception for 1 month (females) or 3 months (males) after their last dose of study treatment.
Normal systemic blood pressure defined as a systolic blood pressure of 90 to 140 mmHg and a diastolic blood pressure of 50 to 90 mmHg.
History of cardiovascular disease (e.g., hypertension, arrhythmia, heart failure, Long QT Syndrome, or other conditions/diseases causing prolongation of the QT/QTc interval).
A prolongation of QT/QTc interval (e.g., repeated demonstration of a QT/QTc interval
>450 ms before study treatment administration) at screening, admission or pre-dose on Day 1.
Any clinically important abnormalities in resting ECG that may interfere with the interpretation of QTc interval changes at screening, admission or pre-dose on Day 1.
Prior exposure to dexpramipexole.
Treatment with pramipexole or any dopamine agonist within 1 year.
Treatment with another investigational drug or approved therapy for investigational use within 30 days, or 5 half-lives (whichever is longer), or in follow up for any other drug, biologic, or device study.
Currently active infection or serious infection (e.g., pneumonia, septicemia) within the 2 months prior to Day -2 as determined by the Investigator.
Female subjects who are pregnant, currently breastfeeding, or attempting to conceive during the study.
All locations for NCT01449578
United States (1)
Overland Park, Kansas, United States
View full eligibility
Tris trial is registered with FDA with number: NCT01449578. The sponsor of the trial is Knopp Biosciences and it is looking for 63 volunteers for the current phase.
Official trial title: A Randomized, Blinded, Placebo-Controlled Ascending Dose Study of the Safety and Pharmacokinetics of Dexpramipexole in Healthy Volunteers
1What's a trial
4Get in touch
What's a trial
Not sure you're well informed about clinical trials? Learn more about their benefits, risks and other important details.
Enter your details like condition, age, gender and other preferences and we will show you a list of all relevant clinical trials.
Review the summary of the selected clinical trial and all the locations near you in order to see if it's of interest to you.
Get in touch
You've found an interesting trial? We'll need a bit more information about you so we can connect you to the doctor in charge.
Some people want to consult their doctor before considering participation in a clinical trial. This is absolutely normal as your doctor should know your medical history and should be able to advise you. If you want you can easily share the information for this trial with your doctor by clicking on the button below.